Why Lantheus Holdings, Inc.’s (LNTH) Stock Is Down 5.33%
As of Tuesday, July 28, Lantheus Holdings, Inc.’s LNTH share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. LNTH
$99.64
-1.36
-1.35%
July 31, 2026 4:00:00 PM
EST
Volume: 1,022,015
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Commentary & Analysis
Is Lantheus Holdings, Inc. (LNTH) Overvalued?
We dive into why Lantheus Holdings, Inc. (LNTH) could be considered overvalued on 2026-07-27, based on AAII’s Value Score and Grade.Michael Rose
Which Is a Better Investment, Butterfly Network, Inc. or Lantheus Holdings, Inc. Stock?
Learn more about whether Butterfly Network, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Lantheus Holdings, Inc. or Insulet Corporation Stock?
Learn more about whether Lantheus Holdings, Inc. or Insulet Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
What You Need to Know About Lantheus Holdings, Inc.'s Q2 Earnings
Lantheus Holdings, Inc.'s fiscal Q2 earnings report was released on Thursday, May 07. Let's dive in to see if (LNTH) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | LNTH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,575.7 | $334.8 | 71% |
|
| Shares Out (Mil) | 65.8 | 41.7 | 54% |
|
| Institutional Ownership | 98.4% | 77.3% | 79% |
|
| Float (Mil) | 58.4 | 34.7 | 51% |
|
| Beta | -0.08 | 0.86 | 4% |
|
| Avg Daily Volume (000s) | 1,016 | 266 | 71% |
|
| Price Change (52-week) |
39.9% | 60.7% | 75% |
|
| Growth | LNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 35.3% | 11.8% | 92% |
|
| Net Income (5yr) | 80.8% | (5.8%) | 98% |
|
| EPS (5yr) | 73.3% | 10.7% | 98 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (112.3%) | (16.1%) | 0% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 12 | |
| Current EPS | $1.294 | $5.356 | $6.309 | |
| Month Ago EPS | $1.301 | $5.333 | $6.387 | |
| # Rev Up | 1 | 2 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.259 | $5.189 | $6.293 | |
| Year/Year Chg | (28.1%) | 57.1% | 122.5% | |
| Financials | LNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,546 | $152 | 57% |
|
| Net Income (TTM) (Mil) | $279 | ($11) | 72% |
|
| EPS (TTM) | $4.196 | ($0.500) | 84% |
|
| Operating Cash Flow (TTM) (Mil) | $408 | ($2) | 69% |
|
| Net Cash Flow (TTM) (Mil) | ($440) | $1 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $625 | $22 | 62% |
|
| Enterprise Value (Q1) (Mil) | $6,186 | $304 | 66% |
|
| Valuation | LNTH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.42 | 2.88 | 80% |
|
| P/E | 24.3 | 30.5 | 60% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 1.9 | 14% |
|
| Ratios | LNTH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.5% | 59.1% | 73% |
|
| Net Margin | 18.0% | (7.7%) | 77% |
|
| ROA | 12.7% | (13.7%) | 91% |
|
| ROE | 23.5% | (15.9%) | 83% |
|
| Liabilities to Assets | 48.3% | 44.9% | 40% |
|
| F-Score | 5 | 4 | 51% |
|
Lantheus Holdings, Inc. did not pass any screens on 7/30/2026.
